检索结果-南通市图书馆

Use of arterial conduit for arterial revascularization during liver and multivisceral transplantation

Chinese Medical Journal 2011年第19期124卷 2986-2989页

作者： ma yi li qiang ye zhi-ming zhu xiao-feng he xiao-shun Organ Transplantation Center the First Affiliated Hospital Sun Yat-sen University Guangzhou Guangdong 510080 China

Background At present, revascularization is still one of the most critical technologies in orthotopic liver transplantation （OLT）. hepatic artery （HA） variations occur frequently in both donors and recipients. Moreover, there are always some pathological changes in the recipient hepatic artery. If handled improperly, it may cause complications after ***, arterial conduit could be used in primary OLT, re-OLT and multiple-OLT. This study aimed to investigate the indications, methods and techniques with usage of arterial conduit for HA revascularization during adult *** We reviewed 1200 patients of consecutive OLTs performed during 2000-2009 in the First Affiliated Hospital of Sun Yat-sen University. Of these patients, 48 recipients with artery variations received HA revascularization with usage of arterial conduit and special postoperative managements. The indications, methods, techniques, and the managements of postoperative complications in adult OLT with usage of arterial conduit for HA revascularization were *** In 48 cases with artery bypass, the arterial conduit were anastomosed between donor hepatic artery and recipient infrarenal aorta （n=32）, between donor hepatic artery and recipient suprarenal aorta （n=10）, and between donor upper abdominal organ cluster artery and recipient suprarenal aorta （n=6）. The technique was applied in 4% （48/1200 cases） of the whole OLTs performed in the same period, and the patency rate of the conduits was 100%. Forty patients （83.3%） survived, and the average survival time was 3.9 years. Eight patients （16.7%） died （all due to tumor recurrence）,while the average survival time was 1.2 years. All these patients have not experienced artery-related complications in their survival *** When recipient HA has variations or pathological changes in OLT, the donor artery should be anastomosed to recipient abdominal aorta with an arterial conduit to achieve satisfactory outcomes. For arteri

关键词： liver transplantation hepatic artery iliac artery graft

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Simultaneous liver and kidney transplantation： analysis of a single-center experience

引用

Chinese Medical Journal 2010年第10期123卷 1259-1263页

作者： ma yi WANG Guo-dong he xiao-shun li qiang li Jun-liang zhu xiao-feng WANG Chang-xi Organ Transplantation Center the First Affiliated Hospital Sun Yat-Sen University Guangzhou Guangdong 510080 China

Background Simultaneous liver and kidney transplantation （SLKT） has been proven to be a favorable treatment for combined renal and hepatic end-stage disease. However, recipients receiving SLKT have a long medical history, poor general condition that is often accompanied by anemia, hypoalbuminemia, coagulopathy, water-electrolyte imbalance and acid-base disorders. This study aimed to explore the indications, surgical techniques, therapeutic experience, prevention and treatment of postoperative complications of SLKT. Methods The clinical data of 22 SLKTs cases performed at the First Affiliated Hospital of Sun Yat-sen University from January 2001 to December 2008 were retrospectively studied. Indications for SLKT, surgical techniques, perioperative fluid management, immunosuppressive regimen and experience in prevention and treatment of postoperative complications were analyzed. Results All operations were successfully performed. Postoperative complications occurred in 13 cases （59.1%）, including pleural effusions （7）, intra-abdominal bleeding （2）, biliary complications （2）, repeated upper gastrointestinal bleeding （1）, and acute liver graft rejection （1）. All complications were treated conservatively. In this study, there were five deaths during follow-up, in which three perioperative deaths occurred due to serious conditions. Mortality at 3 months was 13.6%. The one and three year patient survival rate was 81.3% and 73.9% respectively. Conclusions SLKT is an effective therapy for end-stage liver disease with chronic renal failure or severe damage to renal function. It is a complex surgical procedure, causing a large disturbance of circulation and fluid balance, and more postoperative complications. The SLKT surgical techniques selected are based on the experience of surgeons, the anatomy of the recipient and primary diseases. It is essential to use the correct perioperative fluid management, reasonable immunosuppressive regimen, and prevention and treatment of postop

关键词： liver transplantation kidney transplantation treatment

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

CEPC Technical Design Report

引用

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert maarten Boonekamp marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai yijian Cai yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen mali Chen mingjun Chen mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen xiaoyu Chen Xin Chen Xun Chen Xurong Chen ye Chen ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho ming-Chung Chu xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui xiaohao Cui Zhaoyuan Cui Brunella D'Anzi ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis

引用

Chinese Medical Journal 2019年第24期132卷 2899-2904页

作者： Chun li Yan Zhang Hui Song Jie Gao Dong-Bao Zhao Qi zhu Dong-yi he li Wang Xiang-Pei li Xu-Dong liu Wei-Guo xiao Xin-Yu Wu Hua-Xiang Wu Wei Tu Shao-Xian Hu Xin Wang zhi-Jun li zhi-Min Lu Zhan-Yun Da Bo liang xiao-Min liu Jin-Wei Zhao ling li feng Han Wu-Fang Qi Wei Wei Xu ma Zhen-Bin li Gui-Min Zheng feng-xiao Zhang yi li You-lian Wang Guang-Hui ling Jin-Wei Chen xiao-qiang Hou Jing Zhang Qing-Ping Chen Chang-lian liu Yan Zhang Jia-shun Zeng Qing-Hua Zou Yong-Fei Fang yin Su Zhan-Guo li Department of Rheumatology and Immunology Peking University People's HospitalBeijing 100044China Department of Rheumatology and Immunology Beijing Jishuitan HospitalBeijing 100035China Department of Rheumatology and Immunology Changhai HospitalShanghai 200433China Department of Rheumatology Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western MedicineShanghai 200052China Department of Rheumatology and Immunology Anhui Provincial HospitalHefeiAnhui 230001China Department of Rheumatology and Immunology The First Hospital of China Medical UniversityShenyangLiaoning 110001China Department of Rheumatology The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiang 310009China Department of Rheumatology and Immunology Tongji HospitalWuhanHubei 430030China Department of Rheumatology The First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233004China Department of Rheumatology and Immunology Affiliated Hospital of Nantong UniversityNantongJiangsu 226001China Department of Rheumatology and Immunology The Hospital of Shunyi District BeijingBeijing 101300China Department of Infection and Immunology Tianjin Union Medical CenterTianjin 300121China Department of Rheumatology and Immunology Tianjin First Central HospitalTianjin 300192China Department of Rheumatology and Immunology Tianjin Medical University General HospitalTianjin 300052China Department of Rheumatology and Immunology Peace HospitalShijiazhuangHebei 050000China Department of Rheumatology and Immunology Hebei General HospitalShijiazhuangHebei 050051China Department of Rheumatology Jiangxi Provincial People's HospitalNanchangJiangxi 330006China Division of Rheumatology and Immunology The Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China Department of Rheumatology and Immunology The First College of Clinical Medical Science of China Three Gorges University&Yichang Central People's HospitalYichangHubei 443003China Department of Rheu

Background:Clinical outcomes of undifferentiated arthritis(UA)are diverse,and only 40%of patients with UA develop rheumatoid arthritis(RA)after 3 *** predictive markers at disease onset for further intervention is ***,our objective was to analyze the clinical outcomes of UA and ascertain the predictors for RA ***:We performed a prospective,multi-center study from January 2013 to October 2016 among Chinese patients diagnosed with UA in 22 tertiary-care *** and serological parameters were obtained at ***-up was undertaken in all patients every 12 weeks for 2 *** factors of disease progression were identified using multivariate Cox proportional hazards ***:A total of 234 patients were recruited in this study,and 17(7.3%)patients failed to follow up during the *** the 217 patients who completed the study,83(38.2%)patients went into *** patients who developed RA had a higher rheumatoid factor(RF)-positivity(42.9%vs.16.8%,χ^2=8.228,P=0.008),anti-cyclic citrullinated peptide(CCP)antibodypositivity(66.7%vs.10.7%,χ^2=43.897,P<0.001),and double-positivity rate of RF and anti-CCP antibody(38.1%vs.4.1%,χ^2=32.131,P<0.001)than those who did ***-CCP antibody but not RF was an independent predictor for RA development(hazard ratio 18.017,95%confidence interval:5.803–55.938;P<0.001).Conclusion:As an independent predictor of RA,anti-CCP antibody should be tested at disease onset in all patients with UA.

关键词： Anti-cyclic citrullinated peptide antibody Arthritis,Rheumatoid Rheumatoid factor Undifferentiated arthritis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

引用

hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-yi Su Sun-Bin ling Qiao-Nan Shan Xu-Yong Wei Rui Wang Chang-Ku Jia li zhuang Tian Shen li-Min Ding zhi-Dan Xu Lai-Bang Luo li-Bo Sun Guang-ming li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su zhi-Hai Peng Ren Lang Tao Jiang qiang he lin-Sen ye Yang Yang Yu-Ting he Wen-zhi Guo liu-Gen Lan Xu-Yong Sun Dong Chen zhi-Shui Chen Da-Wei Zhou Shao-Jun ye Qi-Fa ye Min Tian Jian-Hua Shi Bo Wang Jiang liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-yin Yang Pu-Sen Wang lin Zhong Jing-Sheng ma Qi-Gen li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan Wang Zi-qiang li Mu-Jian Teng Jun-Jie li Wen-Tao Jiang Jian-Hua li Quan-Bao Zhang Ning-Qi zhu Zheng-Xin Wang Kang he qiang Xia Shao-Hua Song zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen ying-Peng Zhao li li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie xiao-shun he zhi-Yong Guo Shu-Sen Zheng xiao Xu Department of hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of hepatobiliary Surgery The First Affiliated Hos

mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents hepatocellular carcinoma liver transplantation Conversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A new prognostic histopathologic classification of nasopharyngeal carcinoma

引用

Chinese Journal of Cancer 2016年第6期35卷 30-45页

作者： Hai-Yun Wang yih-Leong Chang Ka-Fai To Jacqueline S.G.Hwang Hai-qiang mai Yan-Fen feng Ellen T.Chang Chen-Ping Wang Michael Koon ming Kam Shie-Lee Cheah ming Lee li Gao Hui-Zhong Zhang Jie-Hua he Hao Jiang Pei-Qing ma xiao-Dong zhu liang Zeng Chun-Yan Chen Gang Chen ma-Yan Huang Sha Fu Qiong Shao An-Jia Han Hai-Gang li Chun-Kui Shao Pei-Yu Huang Chao-Nan Qian Tai-Xiang Lu Jin-Tian li Weimin ye Ingemar Ernberg Ho Keung Ng Joseph T.S.Wee yi-Xin Zeng Hans-Olov Adami Anthony T.C.Chan Jian-Yong Shao State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Sun Yat-sen University Cancer Center Department of Molecular Diagnostics Sun Yat-sen University Cancer Center Department of Pathology National Taiwan University HospitalNational Taiwan University College of Medicine Department of Anatomical and Cellular Pathology Hong Kong Cancer Institute and Sir YK Pao Centre for CancerFaculty of MedicineThe Chinese University of Hong Kong Department of Pathology Singapore General Hospital Department of Nasopharyngeal Carcinoma Sun Yat-sen University Cancer Center Department of Pathology Sun Yat-sen University Cancer Center Division of Epidemiology Department of Health Research and PolicyStanford University School of Medicine health Sciences Practice ExponentInc. Department of Otolaryngology National Taiwan University HospitalNational Taiwan University College of Medicine Department of Clinical Oncology Hong Kong Cancer Institute and Sir YK Pao Centre for CancerFaculty of MedicineThe Chinese University of Hong Kong Division of Radiation Oncology National Cancer CenterSingapore Department of Radiation Oncology Cancer Institute and HospitalChinese Academy of Medical Sciences Department of Radiation Oncology The Affiliated Hospital of Bengbu Medical College Department of Pathology Cancer Institute and HospitalChinese Academy of Medical Sciences Department of Radiation Oncology Guangxi Medical University Department of Pathology Hunan Provincial Cancer Hospital Department of Radiation Oncology Sun Yat-sen University Cancer Center Department of Pathology Fujian Provincial Cancer Hospital Department of Pathology The First Affiliated HospitalSun Yat-sen University Department of Pathology Sun Yat-sen Memorial HospitalSun Yat-sen University Department of Pathology The Third Affiliated HospitalSun Yat-sen University Department of Experiment Research Sun Yat-sen University Cancer Center Department of Medical Epidemiology and Biostatistics Karolinska Institutet Departments of Mi

Background:The current World health Organization(WHO) classification of nasopharyngeal carcinoma(NPC) con?veys little prognostic *** study aimed to propose an NPC histopathologic classification that can poten?tially be used to predict prognosis and treatment ***:We initially developed a histopathologic classification based on the morphologic traits and cell differentia?tion of tumors of 2716 NPC patients who were identified at Sun Yat?sen University Cancer Center(SYSUCC)(training cohort).Then,the proposed classification was applied to 1702 patients(retrospective validation cohort) from hospitals outside SYSUCC and 1613 patients(prospective validation cohort) from *** efficacy of radiochemotherapy and radiotherapy modalities was compared between the proposed *** used Cox proportional hazards models to estimate hazard ratios(HRs) with 95% confidence intervals(CI) for overall survival(OS).Results:The 5?year OS rates for all NPC patients who were diagnosed with epithelial carcinoma(EC;3708 patients),mixed sarcomatoid?epithelial carcinoma(MSEC;1247 patients),sarcomatoid carcinoma(SC;823 patients),and squamous cell carcinoma(SCC;253 patients) were 79.4%,70.5%,59.6%,and 42.6%,respectively(P hemotherapy significantly improved survival compared with radiotherapy alone for patients with EC(HR 49–0.75),and possibly for those with SCC(HR = 0.67,95% CI = 0.56–0.80),MSEC(HR = 0.58,95% CI = 0..74–1.28).= 0.63;95% CI = 0.40–0.98),but not for patients with SC(HR = 0.97,95% CI = 0Conclusions:The proposed classification offers more information for the prediction of NPC prognosis compared with the WHO classification and might be a valuable tool to guide treatment decisions for subtypes that are associ?ated with a poor prognosis.

关键词： Nasopharyngeal carcinoma Pathologic classification Prognosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

原位肝移植联合胰头十二指肠切除根治肝门部胆管癌

引用

中华外科杂志 2006年第5期44卷 302-305页

作者：何晓顺张劭朱晓峰计勇曾纪晓马毅王东平鞠卫强巫林伟李志黄洁夫中山大学附属第一医院器官移植中心广州510080 中山大学附属第一医院病理科广州510080 中国协和医科大学

目的探讨原位肝脏移植联合胰头十二指肠切除根治复杂肝外胆管癌的方法及疗效。方法结合国外临床经验和肝外胆管癌的生物学特点,对1例B ismuth-CorletteⅣ型肝外胆管癌侵犯肝内二级胆管及胆总管下段的患者,实施原位肝脏移植联合胰头十二... 详细信息

目的探讨原位肝脏移植联合胰头十二指肠切除根治复杂肝外胆管癌的方法及疗效。方法结合国外临床经验和肝外胆管癌的生物学特点,对1例B ismuth-CorletteⅣ型肝外胆管癌侵犯肝内二级胆管及胆总管下段的患者,实施原位肝脏移植联合胰头十二指肠根治性切除。采用链霉素-卵白素-生物素(LSAB)的免疫组织化学技术,检测切除的病理标本中胆管上皮细胞角蛋白CK9和CK17、癌胚抗原、肝细胞蛋白,确认肿瘤组织学来源。术后给予他克莫司联合甲泼尼龙片抗排斥治疗。同时,拉米夫定联合大剂量乙型肝炎免疫球蛋白静脉滴注预防乙型肝炎复发,术后定期随访。结果术后移植肝的肝功能恢复顺利,血清胃肠道肿瘤标志癌胚抗原、CA19-9、CA125均降至正常范围。随访14个月至今,移植肝及消化功能良好,患者健康并恢复术前工作。结论对无远处转移和腹腔播散,且常规手术无法根治的浸润型肝门部胆管癌B ismuth-CorletteⅣ型,可考虑实施全肝、肝十二指肠韧带联合胰头十二指肠整块切除术根治肿瘤。然后行同种异体原位肝移植并重建消化道。该方法可能有利于提高肿瘤的切除率和患者长期生存率。

关键词：肝移植胰头十二指肠切除术胆管癌肝门部

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

肝移植术后潜在免疫耐受者外周血自然杀伤细胞、调节性T细胞和记忆性T细胞的表达及其临床意义

引用

中华实验外科杂志 2012年第5期29卷 949-952页

作者：邓斐文朱晓峰马毅何晓顺郭志勇刘龙山李强中山大学附属第一医院器官移植科广州510080

目的探讨肝移植术后潜在免疫耐受者免疫状态，为临床指导抗排斥治疗提供依据。方法纳入1999年1月至2007年12月在本中心行肝移植存活至今潜在免疫耐受者29例，分为3～5年组（3Y组）10例，5～11年组（5Y组）19例，另纳入肝移植术后反复排... 详细信息

目的探讨肝移植术后潜在免疫耐受者免疫状态，为临床指导抗排斥治疗提供依据。方法纳入1999年1月至2007年12月在本中心行肝移植存活至今潜在免疫耐受者29例，分为3～5年组（3Y组）10例，5～11年组（5Y组）19例，另纳入肝移植术后反复排斥反应者（RJ）10例，年龄匹配健康对照组（HC）17例；流式检测外周血单个核细胞中自然杀伤（NK）细胞、记忆性T细胞、调节性T细胞（Treg）3个亚群的表达。结果3Y、5Y组CD4＋CD25＋T细胞（3Y：27．56±4．63；5Y：30．07±3．91）、静息性Treg占CD4＋T细胞比例（3Y：0．22±0．05；5Y：0．17±0．03）比RJ组明显升高（CD4’CD25＋T：11．78±4．28；静息性Treg：0．05±0．02）（P〈0．05）；5Y组NK细胞占淋巴细胞比例（29．11±3．31）比RJ组（13．92±3．11）明显升高（P〈0．05）；效应性记忆性CD8’T细胞比例3Y组（12．92±2．05）比RJ组（8．74±1．69）明显升高（P〈0．05）。结论肝移植术后潜在免疫耐受者外周血NK细胞、静息性调节性T细胞和效应性记忆性CD8＋T细胞比例相对排斥反应者明显升高，可作为潜在的耐受标志物。

关键词：肝移植免疫耐受自然杀伤细胞调节性T细胞记忆性T细胞

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Biomarkers of aging

引用

Science China(life Sciences) 2023年第5期66卷 893-1066页

作者： Aging Biomarker Consortium Hainan Bao Jiani Cao Mengting Chen Min Chen Wei Chen xiao Chen Yanhao Chen Yu Chen Yutian Chen zhiyang Chen Jagadish K Chhetri yingjie Ding Junlin feng Jun Guo Mengmeng Guo Chuting he Yujuan Jia Haiping Jiang ying Jing Dingfeng li Jiaming li Jingyi li Qinhao liang Rui liang feng liu xiaoqian liu Zuojun liu Oscar Junhong Luo Jianwei Lv Jingyi ma Kehang mao Jiawei Nie Xinhua Qiao Xinpei Sun xiaoqiang Tang Jianfang Wang Qiaoran Wang Siyuan Wang Xuan Wang Yaning Wang Yuhan Wang Rimo Wu Kai Xia Fu-Hui xiao lingyan Xu yingying Xu Haoteng Yan liang Yang Ruici Yang Yuanxin Yang yilin ying Le Zhang Weiwei Zhang Wenwan Zhang Xing Zhang zhuo Zhang Min Zhou Rui Zhou Qingchen zhu Zhengmao zhu feng Cao Zhongwei Cao Piu Chan Chang Chen Guobing Chen Hou-Zao Chen Jun Chen Weimin Ci Bi-Sen Ding Qiurong Ding feng Gao Jing-Dong JHan Kai Huang Zhenyu Ju Qing-Peng Kong Ji li Jian li Xin li Baohua liu feng liu lin liu qiang liu qiang liu Xingguo liu Yong liu Xianghang Luo Shuai ma Xinran ma zhiyong mao Jing Nie Yaojin Peng Jing Qu Jie Ren Ruibao Ren Moshi Song Zhou Songyang yi Eve Sun Yu Sun Mei Tian Shusen Wang Si Wang Xia Wang xiaoning Wang Yan-Jiang Wang Yunfang Wang Catherine CL Wong Andy Peng Xiang yichuan xiao Zhengwei Xie Daichao Xu Jing ye Rui Yue Cuntai Zhang Hongbo Zhang liang Zhang Weiqi Zhang Yong Zhang Yun-Wu Zhang zhuohua Zhang Tongbiao Zhao Yuzheng Zhao Dahai zhu Weiguo Zou Gang Pei Guang-Hui liu Aging Biomarker Consortium(ABC) Beijing 100101China CAS Key Laboratory of Genomic and Precision Medicine Beijing Institute of GenomicsChinese Academy of Sciences and China National Center for BioinformationBeijing 100101China State Key Laboratory of Stem Cell and Reproductive Biology Institute of ZoologyChinese Academy of SciencesBeijing 100101China Department of Dermatology Xiangya HospitalCentral South UniversityChangsha 410008China Hunan Key Laboratory of Aging Biology Xiangya HospitalCentral South UniversityChangsha 410008China National Clinical Research Center for Geriatric Disorders Xiangya HospitalCentral South UniversityChangsha 410008China Clinic Center of Human Gene Research Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Hubei Clinical Research Center of Metabolic and Cardiovascular Disease Huazhong University of Science and TechnologyWuhan 430022China Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging Huazhong University of Science and TechnologyWuhan 430022China Stem Cell Translational Research Center Tongji HospitalTongji University School of MedicineShanghai 200065China Department of Nuclear Medicine Daping HospitalThird Military Medical UniversityChongqing 400042China CAS Key Laboratory of Nutrition Metabolism and Food SafetyShanghai Institute of Nutrition and HealthUniversity of Chinese Academy of SciencesChinese Academy of SciencesShanghai 200031China Shanghai Key Laboratory of maternal Fetal Medicine Clinical and Translational Research Center of Shanghai First Maternity and Infant HospitalFrontier Science Center for Stem Cell ResearchShanghai Key Laboratory of Signaling and Disease ResearchSchool of Life Sciences and TechnologyTongji UniversityShanghai 200092China The Department of Endovascular Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Key Laboratory of Regenerative Medicine of Ministry of Education Institute of Ageing and Regenerative MedicineJ

Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological *** a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly *** immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this ***,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory *** fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant.

关键词： aging senescence biomarker clock

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

两剂激素联合两剂达利珠单抗及他克莫司的免疫抑制方案在肝移植中的应用

引用

中华外科杂志 2009年第14期47卷 1064-1066页

作者：鞠卫强何晓顺谈雅莉巫林伟邰强胡安斌王东平马毅朱晓峰黄洁夫中山大学附属第一医院器官移植中心广州510080

目的探讨两剂激素联合两剂达利珠单抗及他克莫司（FK506）的免疫抑制方案在肝移植中应用的安全性及有效性。方法中山大学附属第一医院器官移植中心2006年9月至2008年3月共实施成人肝移植74例，排除3例血型不合、4例围手术期死亡外，余6... 详细信息

目的探讨两剂激素联合两剂达利珠单抗及他克莫司（FK506）的免疫抑制方案在肝移植中应用的安全性及有效性。方法中山大学附属第一医院器官移植中心2006年9月至2008年3月共实施成人肝移植74例，排除3例血型不合、4例围手术期死亡外，余67例纳入本研究，其中男性54例，女性13例，年龄28～66岁，平均（46．9±8．7）岁。将67例成人肝移植患者随机分为两组：传统免疫抑制方案（激素3个月撤离）组（n=35）和两剂激素免疫抑制方案组（n=32），比较两组术后代谢并发症、感染（含细菌、真菌及巨细胞病毒感染）及排斥反应的发生率的差异。结果两组患者的术后早期高血糖发生率，高血糖患者使用胰岛素的平均剂量，随访期内糖尿病、高血压及感染的发生率的差异有统计学意义（P〈0．05）；术后早期高血压发生率及随访期内排斥反应的发生率和高脂血症发生率无明显差异（P〉0．05）。结论两剂激素的免疫抑制方案是安全有效的，其不增加急性排斥反应的发生率，并可显著减少长期使用激素引起的各种不良反应及并发症的发生。

关键词：肝移植免疫抑制剂达利珠单抗他克莫司

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：